Get the Stockscreener App
9.72
2.70%
-0.27
After Hours:
9.91
0.19
+1.95%
Nurix Therapeutics Inc stock is traded at $9.72, with a volume of 401.51K.
It is down -2.70% in the last 24 hours and down -16.28% over the past month.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
See More
Previous Close:
$9.99
Open:
$9.74
24h Volume:
401.51K
Relative Volume:
0.42
Market Cap:
$741.05M
Revenue:
$54.55M
Net Income/Loss:
$-193.57M
P/E Ratio:
-3.3633
EPS:
-2.89
Net Cash Flow:
$-181.86M
1W Performance:
+1.67%
1M Performance:
-16.28%
6M Performance:
-55.92%
1Y Performance:
-35.93%
1-Day Range:
$9.545
$9.86
1-Week Range:
$9.25
$10.14
52-Week Range:
$8.18
$29.56
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Name
Nurix Therapeutics Inc
Sector
Industry
Phone
(415) 660-5320
Address
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Compare NRIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
9.72 | 728.81M | 54.55M | -193.57M | -181.86M | -2.89 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-25 | Initiated | Leerink Partners | Market Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-11-24 | Initiated | Jefferies | Buy |
| Sep-06-24 | Resumed | Robert W. Baird | Outperform |
| Jul-31-24 | Initiated | Truist | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-09-23 | Initiated | Barclays | Overweight |
| Feb-28-23 | Initiated | Oppenheimer | Outperform |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Dec-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-30-21 | Resumed | Piper Sandler | Overweight |
| Apr-30-21 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Nov-19-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Stifel | Buy |
View All
Nurix Therapeutics Inc Stock (NRIX) Latest News
Point72 Asset Management L.P. Buys Shares of 872,959 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
D. E. Shaw & Co. Inc. Acquires 40,001 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Deutsche Bank AG Sells 323,485 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Soleus Capital Management L.P. Has $39.62 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
97,889 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Purchased by Velan Capital Investment Management LP - MarketBeat
Vestal Point Capital LP Purchases 60,000 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Northern Trust Corp Grows Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Jacobs Levy Equity Management Inc. Buys Shares of 229,369 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Nurix Therapeutics reports stockholder voting results - Investing.com
Ensign Peak Advisors Inc Acquires 194,673 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) is Patient Square Capital LP's 6th Largest Position - MarketBeat
Parkman Healthcare Partners LLC Has $10.03 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Cubist Systematic Strategies LLC Acquires Shares of 124,025 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Integral Health Asset Management LLC - MarketBeat
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listin - GuruFocus
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference - TradingView
Nurix Therapeutics Announces Presentations of Clinical Data at t - GuruFocus
Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma - The Manila Times
Nurix Therapeutics to Present Phase 1a/b Clinical Trial Data on Bexobrutideg (NX-5948) for CLL and Waldenström Macroglobulinemia at EHA 2025 and 18-ICML Conferences - Nasdaq
Breakthrough Blood Cancer Treatment: Nurix's BTK Degrader Shows Promising Clinical Results in CLL Patients - Stock Titan
Where are the Opportunities in (NRIX) - news.stocktradersdaily.com
Why Nurix Therapeutics (NRIX) Is Among the Best Low Priced Biotech Stocks to Buy Now - Insider Monkey
10 Best Low Priced Biotech Stocks to Buy Now - Insider Monkey
Shareholders Will Probably Hold Off On Increasing Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) CEO Compensation For The Time Being - simplywall.st
Voya Investment Management LLC Acquires 34,811 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
135,903 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Purchased by First Trust Advisors LP - MarketBeat
Raymond James Financial Inc. Takes $1.03 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Deep Track Capital LP Sells 868,104 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Invesco Ltd. Decreases Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Boxer Capital Management LLC Makes New Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by JPMorgan Chase & Co. - MarketBeat
RA Capital Management L.P. Acquires Shares of 1,333,333 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Price T Rowe Associates Inc. MD - MarketBeat
Needham & Company LLC Reaffirms "Buy" Rating for Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
Darwin Global Management Ltd. Invests $3.08 Million in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Schonfeld Strategic Advisors LLC Boosts Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Lord Abbett & CO. LLC Boosts Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
(NRIX) Trading Signals - news.stocktradersdaily.com
Nurix Therapeutics Inc Stock (NRIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
17.27%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):